Novel Recombinases and Target Sequences


This invention is a method to identify serine recombinases for the manipulation of the mammalian genome. There are a number of specific applications including: incorporating in an inducible positive or negative feedback loop allowing the monitoring and modeling of mammalian cellular behavior or the integration of peptides, RNAs and proteins for enhanced controlled or continuous therapeutic expression.

Problem Addressed

Programming mammalian cells with large synthetic gene networks can significantly facilitate elucidating complex regulatory cellular mechanisms, implementing new useful biological functions and accelerating the design of novel tailor-made therapeutic treatments. Complex, stable and heritable programming of mammalian cells by genomic engineering is limited by the requirement to pre-integrate a natural recombination site at single or multiple genomic (chromosomal) loci, thus necessitating the identification of programmable orthogonal (independently acting) recombinases that can be directly targeted sequentially or simultaneously to the endogenous sequences of choice in the mammalian genome. However, only a handful of these enzymes have yet been discovered and are extremely hard to engineer given the complexity of the site‐specific recombination mechanism. This technology includes the discovery of new large serine recombinases, shown to be the most promising ones in terms of efficiency and specificity for the manipulation of mammalian genomes, and procedures to identify more serine recombinases.


This technology includes new large serine recombinases identified from recently sequenced mycobacteriophage genomes and a dedicated plasmid rescue system to identify the specific attB/attP recombination sites recognized by these recombinases. The ability of multiplex integration by using orthogonal sites could help to integrate a variety of different sequences, including circuits containing more than one sequence each, at different locations within a genome, which is helpful in preventing interference between circuits or attaining higher levels of expression. The inventors created a script to scan phage genomes and identify putative large serine recombinases as well as a suite of plasmids to enable the discovery of their recombination sites in their natural host and to transpose the system in E. coli and mammalian cells. The system was validated by identifying 26 new large serine recombinases from 400 Mycobacteriophage genomes, from which 4 were using new recombination sites.


  • Identify serine recombinases for varied uses in synthetic biology
  • Can integrate in a variety of sequences at different locations in the genome

Intellectual Property

IP Type: Published PCT Application

IP Title: Novel Recombinases and target sequences 

IP Number: WO 2017-127612


IP Type: Granted US Patent

IP Title: Novel Recombinases and target sequences 

IP Number: 10,731,153